HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma
about
Biomarker development in MET-targeted therapyFibroblast growth factor receptor signaling as therapeutic targets in gastric cancerClinical significance of MET in gastric cancerCompanion diagnostics for the targeted therapy of gastric cancerGastrointestinal cancers in the era of theranostics: Updates and future perspectivesBeyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancersMolecular predictive markers in tumors of the gastrointestinal tractIntra-Tumoral Heterogeneity of HER2, FGFR2, cMET and ATM in Gastric Cancer: Optimizing Personalized Healthcare through Innovative Pathological and Statistical AnalysisDiscretization of Gene Expression Data Unmasks Molecular Subgroups Recurring in Different Human Cancer TypesCirculating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification.Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers.HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development.Targeting MET Amplification as a New Oncogenic Driver.Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.Patient-Derived Gastric Carcinoma Xenograft Mouse Models Faithfully Represent Human Tumor Molecular Diversity.Detection of MET Gene Copy Number in Cancer Samples Using the Droplet Digital PCR Method.Targeted therapy in gastroesophageal cancers: past, present and future.Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.Identifying therapeutic targets in gastric cancer: the current status and future directionMET in gastric cancer--discarding a 10% cutoff ruleMolecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma.PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.Clinicopathological Significance and Diagnostic Accuracy of c-MET Expression by Immunohistochemistry in Gastric Cancer: A Meta-Analysis.Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithmInvestigational therapies targeting the ErbB family in oesophagogastric cancer.Targeting the hepatocyte growth factor/mesenchymal epithelial transition pathway in gastric cancer: biological rationale and clinical applications.Role of c-mesenchymal-epithelial transition pathway in gastric cancer.Prognostic significance of Daxx NCR (Nuclear/Cytoplasmic Ratio) in gastric cancer.MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation.C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives.Gene of the month: HGF.The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer.MET overexpression and amplification define a distinct molecular subgroup for targeted therapies in gastric cancer.Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models.Profiling cancer-associated genetic alterations and molecular classification of cancer in Korean gastric cancer patients.Engineered Breast Cancer Cell Spheroids Reproduce Biologic Properties of Solid Tumors.Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines.Synergistic antitumor effects of cMet inhibitor in combination with anti-VEGF in colorectal cancer patient-derived xenograft models.
P2860
Q26751332-D47A7A9F-EC51-4797-8C7B-3C5B88C41439Q26764932-571E5A6D-9A81-4EE9-B312-13F4BD75216CQ26776190-7B4301CE-ED97-4CEA-BD5F-800C1B70D89BQ26780298-B7B7F6E8-094A-42B2-BBAB-D2F92018FFCFQ26801215-A10331AD-C2C5-4EA3-8C35-8F1B4B194E5AQ28066550-46C29325-B8E7-49EE-91CF-34225E63C52CQ28070583-4C4DDDFF-6001-444F-B491-DDAC21A44EB8Q28551059-0B07EDD6-320A-4120-A342-DE7EEE4CDAD1Q31122277-8D173886-9D90-4E88-9C79-FD60226D910BQ33688625-384724D6-639A-4274-8701-59538733BA0BQ33779701-B4DF30E3-62D9-4C6D-AA1B-757CF1E0F735Q33917507-3D6FA224-EA17-4EB2-99F9-9C407C15A68DQ34309927-B40C7113-A38C-4458-B720-837A55EEA990Q35586700-70D589FC-67A6-47D4-AD6B-6A7244CDFF11Q35719104-D56D527D-A282-4B48-BC24-3CABD2E3E3A5Q35893861-B4CD3B63-6A58-42F6-AB7C-2FA9B9BB092CQ36294579-2524F1F0-3FB1-4497-95E8-E673C12BABAFQ36307708-B4098CF2-47AE-4563-BA7B-393F416E6C7DQ36398732-8690F1D7-4532-472E-8F52-C5837DF5F61FQ36554574-183B8629-823B-4DD2-A7E3-FCCB6F6582F2Q36750684-6A4350CD-8F3F-4D2F-8FB5-147A9FBB1363Q37252398-1518E5BB-3F35-43EB-ABEC-BB3870B86E5EQ37342442-62A8E59B-AFEA-4963-9945-89312B0FB0D1Q37687784-C83BC7FF-B9DF-4BB6-94B6-2AD033A7642EQ38221886-07C043D3-8EB9-4E13-9F42-FCFE862B35DDQ38263575-5488CFEC-7457-48EA-AD04-13A7C32C4B2EQ38424220-FA8F75D3-CEA5-46FE-82F4-30F8C60623B6Q38622607-A1ECBDF1-5069-450F-AB48-590393483E5DQ38675350-C08781A5-7821-40AB-8390-DCFBB6D4248DQ38741697-D7B488FB-0D0E-4738-B589-2F249F0250E7Q38756848-27E2CF3A-88FB-4C0C-9FF2-FABA08186CAFQ38771978-8E888C52-01C8-4225-8212-EF3E61C3529CQ38806819-2B4014AB-E7A0-4C3C-8D4D-A260B4DF61FBQ38824065-41CF7550-9611-4BEE-9167-10CF8AB762DAQ38832652-99E481D3-1329-4A5C-A1E8-417E6D068E15Q38953922-02911392-3236-49B8-B7FA-E8CB83D5ACADQ42378389-CA75149E-40BB-4F07-8BD3-8A58FEDAB192Q42835560-529F07FC-66E4-4FE1-B070-3A6DF1DD9CF8Q47564950-61B2F739-7680-4DD6-BAB4-37F2C31BC6D5Q52576043-6EE20707-ED9F-42B1-8CF0-47F68D5B62C5
P2860
HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
HER2, MET and FGFR2 oncogenic ...... therapies in gastric carcinoma
@en
HER2, MET and FGFR2 oncogenic ...... herapies in gastric carcinoma.
@nl
type
label
HER2, MET and FGFR2 oncogenic ...... therapies in gastric carcinoma
@en
HER2, MET and FGFR2 oncogenic ...... herapies in gastric carcinoma.
@nl
prefLabel
HER2, MET and FGFR2 oncogenic ...... therapies in gastric carcinoma
@en
HER2, MET and FGFR2 oncogenic ...... herapies in gastric carcinoma.
@nl
P2093
P2860
P356
P1476
HER2, MET and FGFR2 oncogenic ...... therapies in gastric carcinoma
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.2014.61
P407
P577
2014-02-11T00:00:00Z